The Future of GI Care Starts with Salvo Health

June 3, 2025

By The Artemis Fund
The Artemis Fund believes technology can create prosperity for all. With offices in New York, Texas, Massachusetts, and Nevada, Artemis leads seed rounds for companies creating resilient families, individuals, and businesses across the US.
Imagine you’re a working parent in a small town, juggling deadlines, family meals, and everything in between, while also quietly battling relentless gut pain. You’ve tried eliminating foods, tracking your symptoms, and experimenting with supplements. The nearest specialist is booked for months, leaving you totally alone to connect the dots between your diet, stress levels, microbiome, and symptoms.
Since the pandemic, gut health has taken center stage in the broader wellness conversation. People are paying closer attention to how digestion connects to anxiety, inflammation, and immunity. Telehealth, food-as-medicine, and the brain-gut connection have become mainstream. Yet the traditional GI system in the U.S. is not equipped to meet this rising demand, with most patients facing fragmented care, long wait times, and limited support between visits.
Unmanaged digestive symptoms are now the leading cause of treat-and-release ER visits. GI issues are also among the top four healthcare cost drivers for employers and payers.
At Artemis, we invest in access, particularly for communities and individuals overlooked by conventional care models. Gastrointestinal health is one of the most widespread, yet underserved, areas of need. More than two-thirds of U.S. counties lack a single gastroenterologist, leaving nearly 49M people without local care.
We’re proud to announce our investment in Salvo Health’s Seed Prime round alongside City Light, Human Ventures, Threshold, Alumni Ventures, Felicis, and Torch Capital.
Two out of three Americans experience digestive symptoms weekly, and 25 percent live with a diagnosed GI condition. Together, these issues contribute to an estimated $136B in annual healthcare costs.

Get The Artemis Fund’s stories in your inbox.

Salvo Health, based in New York, New York, is reimagining GI care by delivering a coordinated, insurance-covered program that includes GI specialists, dietitians, psychologists, and health coaches. Through a hybrid model that blends local provider care with app-based support, Salvo expands access, improves outcomes, and reduces strain on GI clinics.
Jeff Glueck, CEO, is a seasoned entrepreneur and former CEO of Travelocity, bringing decades of experience scaling data-driven consumer platforms. Marin Rothenberg, COO, is the former Head of Operations at AbleTo, is a healthcare operations leader who has scaled national clinical infrastructure and brings deep expertise in systems-building and strategic execution. Dr. Erin Hendriks, CMO, is a quadruple board-certified physician and expert in functional and integrative medicine.
The Opportunity
Only 17K GI physicians currently practice in the U.S., and over half are nearing retirement within the next decade
80M+ Americans live with chronic GI or MASLD conditions
17% of counties have fewer than five gastroenterologists
The Solution
At the core of Salvo’s approach is Whole Self Science™, a care model that understands GI symptoms as part of the body’s larger ecosystem. By addressing biology, behavior, and lifestyle together, Salvo supports better outcomes, fewer emergency visits, and improved long-term health.
Through exclusive partnerships with PE-backed GI clinics, Salvo drives both improved patient care and clinic profitability. Their unique go-to-market strategy enables scalable growth while expanding access to millions who have been underserved by the traditional system.
The Impact
Salvo Health’s virtual-first, interdisciplinary model is already driving results. Patients, 86 percent of whom are women, report measurable improvements in quality of life and symptom reduction within just four weeks. By reducing unnecessary ER visits, lowering total medical expenses, and expanding access to high-quality care, Salvo is not just filling a gap in the system, but setting a whole new standard for GI treatment.
We believe once in a generation companies will be built by unexpected founders. If that sounds like you, pitch us here!

Newsletter Signup